Moderna, Inc. (NASDAQ:MRNA – Get Free Report) dropped 3.6% during trading on Monday. The company traded as low as $212.50 and last traded at $215.27. 6,997,765 shares were traded during mid-day trading, a decline of 44% from the average daily volume of 12,547,155 shares. The stock had previously closed at $223.37.
Key Stories Impacting Moderna
Investors following MRNA have been watching these stories:
- Neutral Sentiment: President Stephen Hoge reported sales of roughly 39,000 shares on each of November 16 and 17. Both transactions were made under a pre-arranged Rule 10b5-1 plan, which makes them less conclusive as a signal about management’s near-term outlook. SEC filing
- Negative Sentiment: Recent coverage describes a prolonged decline following a roughly 600% year-to-date rally, raising the possibility of profit-taking and concerns that expectations for a recovery had become stretched. Article Article
- Negative Sentiment: Some reports allege more adverse reactions with Moderna’s mRNA flu vaccine than with standard-dose flu shots. The cited VAERS reports do not, by themselves, establish that the vaccine caused those events, but the claims may add to investor concern about the product. Article
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. TD Cowen restated a “buy” rating on shares of Moderna in a research report on Wednesday, October 21st. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a report on Wednesday, August 19th. Rothschild & Co Redburn lowered shares of Moderna from a “neutral” rating to a “sell” rating and raised their target price for the stock from $40.00 to $81.00 in a research note on Thursday, September 3rd. Evercore boosted their target price on Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. Finally, Berenberg Bank upped their price target on Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research report on Friday, September 11th. Six equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $120.25.
Moderna Stock Performance
The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.47 and a current ratio of 3.62. The firm’s 50-day moving average price is $204.39 and its two-hundred day moving average price is $98.06. The stock has a market cap of $79.63 billion, a price-to-earnings ratio of -27.72 and a beta of 1.16.
Moderna (NASDAQ:MRNA – Get Free Report) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $1.48. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm had revenue of $1.31 billion during the quarter, compared to analysts’ expectations of $890.25 million. During the same period last year, the business earned ($0.51) earnings per share. Moderna’s revenue was up 29.2% compared to the same quarter last year. On average, analysts expect that Moderna, Inc. will post -5.14 EPS for the current fiscal year.
Insider Transactions at Moderna
In other news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the sale, the insider owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the company’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 275,626 shares of company stock worth $50,776,076 in the last 90 days. Insiders own 10.80% of the company’s stock.
Hedge Funds Weigh In On Moderna
Hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new position in Moderna in the second quarter valued at approximately $2,142,877,000. Theleme Partners LLP purchased a new stake in shares of Moderna during the 2nd quarter worth approximately $564,272,000. Aberdeen Group plc lifted its position in shares of Moderna by 6,931.1% during the 3rd quarter. Aberdeen Group plc now owns 1,054,306 shares of the company’s stock worth $203,028,000 after buying an additional 1,039,311 shares during the last quarter. Wellington Management Group LLP boosted its holdings in shares of Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after buying an additional 103,977 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new position in shares of Moderna in the 2nd quarter valued at $161,642,545. 75.33% of the stock is currently owned by hedge funds and other institutional investors.
Moderna Company Profile
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Further Reading
- Five stocks we like better than Moderna
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.
